Premium
Major Histocompatibility Complex Markers in Patients with Nomifensine‐Induced Immune Hemolytic Anemia
Author(s) -
MuellerEckhardt Gertrud,
Giers G.,
Salama A.,
Schendel Dolores J.,
Fass G.,
MuellerEckhardt C.
Publication year - 1988
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1988.tb01615.x
Subject(s) - immunology , nomifensine , immune system , histocompatibility , hemolytic anemia , medicine , major histocompatibility complex , anemia , hemolysis , antigen , human leukocyte antigen , dopaminergic , dopamine
. To evaluate a possible role of major‐histocompatibility‐complex (MHC)‐related immune‐response genes for the selective production of drug‐induced antibodies, HLA class I (ABC), class II (DR, DQ), class III (BF, C2, C4A, C4B) as well as glyoxalase‐1 allotypes were investigated in 26 patients with nomifensine‐induced immune hemolytic anemia. No statistically significant deviations of MHC antigen frequencies were noted. The possible implications of these findings are discussed.